References
- Brahmer JR Pardoll DM . Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol. Res.1 (2), 85–91 (2013).
- Quezada SA Peggs KS Simpson TR Allison JP . Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol. Rev.241 (1), 104–118 (2011).
- Chen L Flies DB . Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat. Rev. Immunol.13 (4), 227–242 (2013).
- Chen Z Laurence A O'Shea JJ . Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin. Immunol.19 (6), 400–408 (2007).
- Kortylewski M Xin H Kujawski M et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell15 (2), 114–123 (2009).
- Kujawski M Zhang C Herrmann A et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res.70 (23), 9599–9610 (2010).
- Hossain DM Panda AK Manna A et al. FoxP3 acts as a cotranscription factor with STAT3 in tumor-induced regulatory T cells. Immunity39 (6), 1057–1069 (2013).
- Gu AD Wang Y Lin L Zhang SS Wan YY . Requirements of transcription factor Smad-dependent and -independent TGF-beta signaling to control discrete T-cell functions. Proc. Natl Acad. Sci. USA109 (3), 905–910 (2012).
- Sitkovsky MV . T regulatory cells. hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol.30 (3), 102–108 (2009).
- Yin H Kanasty RL Eltoukhy AA Vegas AJ Dorkin JR Anderson DG . Non-viral vectors for gene-based therapy. Nat. Rev. Genet.15 (8), 541–555 (2014).
- Zhou J Rossi JJ . Cell-type-specific, aptamer-functionalized agents for targeted disease therapy. Mol. Ther.3, e169 (2014).
- McNamara JO 2nd Andrechek ER Wang Y et al. Cell type-specific delivery of siRNAs with aptamer–siRNA chimeras. Nat. Biotechnol.24 (8), 1005–1015 (2006).
- Dassie JP Giangrande PH . Current progress on aptamer-targeted oligonucleotide therapeutics. Ther. Deliv.4 (12), 1527–1546 (2013).
- Zhou J Li H Li S Zaia J Rossi JJ . Novel dual inhibitory function aptamer–siRNA delivery system for HIV-1 therapy. Mol. Ther.16 (8), 1481–1489 (2008).
- Neff CP Zhou J Remling L et al. An aptamer–siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4+ T cell decline in humanized mice. Sci. Transl. Med.3 (66), 66ra6 (2012).
- Wheeler LA Trifonova R Vrbanac V et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer–siRNA chimeras. J. Clin. Invest.121 (6), 2401–2412 (2011).
- Berezhnoy A Castro I Levay A Malek TR Gilboa E . Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. J. Clin. Invest.124 (1), 188–197 (2014).
- Herrmann A Priceman SJ Kujawski M et al. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J. Clin. Invest.124 (7), 2977–2987 (2014).
- Santulli-Marotto S Nair SK Rusconi C Sullenger B Gilboa E . Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res.63 (21), 7483–7489 (2003).
- Nechaev S. Gao C. Moreira D et al. Intracellular processing of immunostimulatory CpG–siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape. J. Control. Release170, 307–315 (2013).